1. Introduction {#sec1}
===============

Type II Diabetes mellitus (T2DM) has been a major global health problem and affects a large population worldwide \[[@B1], [@B2]\]. T2DM is a multifactorial and genetically heterogeneous disease caused by various risk factors such as insulin resistance, *β*-cell dysfunction, and obesity \[[@B2]--[@B5]\]. Moreover, T2DM may cause acute cardiovascular disease, retinopathy, nephropathy, neuropathy, and kidney-related complications \[[@B5]--[@B7]\]. Therefore, it demands effective drugs with minimal toxicity. The herbal medicines have been used for T2DM for thousands of years and accumulated a great deal of clinical experience. A herbal formula comprises several medicinal plants or animals and thus can affect the biological system through interactions between compounds and cellular targets \[[@B3], [@B8]--[@B17]\]. The main mechanisms of herbal medicines in treating T2DM are that it increases insulin secretion and the sensitivity of insulin, inhibits glucose absorption, and reduces radicals caused by lipid peroxidation \[[@B8]\]. However, the major problem of herbal medicines is lack of scientific and clinical data to evaluate their efficacy and safety.

Network pharmacology proposed by Hopkins is a holistic approach to understand the function and behavior of a biological system at systems level in the context of biological networks and would be the next paradigm for drug discovery \[[@B18]--[@B20]\]. Several efforts have been made to explore the mechanism of herbal medicines such as prediction of the active ingredients and potential targets \[[@B21]--[@B26]\] and screening synergistic drug combinations \[[@B11], [@B27], [@B28]\]. The drug-target network (DTN) which connects drugs and their target proteins is an important biological network and provides an overview of polypharmacology of drugs \[[@B29]--[@B32]\]. Since medicinal plants have multiple compounds and a compound would have several target proteins, the DTN may bridge the gap between medicinal plants and diseases. In this work, we developed a computational approach based on DTN to evaluate the efficacy of medicinal plants.

2. Materials and Methods {#sec2}
========================

2.1. Data Collection and Molecular Docking {#sec2.1}
------------------------------------------

The pathogenesis of T2DM is concerned with various proteins. We retrieved the information of these proteins from KEGG Pathway database \[[@B33]\] and DrugBank \[[@B34]\] ([Figure 1](#fig1){ref-type="fig"}). The pathway of T2DM was downloaded from the KEGG website (<http://www.genome.jp/dbget-bin/www_bget?hsa04930>), and the information of T2DM-related proteins was collected. In DrugBank, we first retrieved the FDA-approved drugs for T2DM and then found the target proteins for each drug. Then we searched the ligand-protein complex structure (x-ray or NMR) for each protein from RCSB protein data bank (<http://www.rcsb.org/pdb/home/home.do>). Finally, thirty-three proteins and their information were listed in [Table 1](#tab1){ref-type="table"}.

The 3D structures of natural products contained in medicinal plants were retrieved from the Universal Natural Product Database (UNPD) which comprised more than 208 thousands of natural products \[[@B35], [@B36]\]. The AutoDock 4.0 \[[@B37], [@B38]\] was adopted to perform the virtual screening, and binding free energy-based docking score (*pK* ~*i*~) was used to evaluate the affinity between each compound and each protein. For each protein, the hetero atoms of the ligand-protein complex structure were deleted and the polar hydrogen atoms were added. The binding site of each protein was defined as a 40  ×  40  ×  40 Å cube around the original ligand with a spacing of 0.375 Å between the grid points. The center of binding site was located in the center of the original ligand. The molecular docking was conducted according to the protocol described previously \[[@B39]\].

2.2. Drug-Target Network Construction and Analysis {#sec2.2}
--------------------------------------------------

The drug-target network was constructed by linking the compound with target protein if the docking score satisfied the thresholds that were used to determine whether the interaction between compound and protein was strong. According to our previous study, the thresholds were set as follow: the docking score should be greater than 7.00 and the score of original ligand of corresponding protein and the top percentage of rank of docking score should be less than 10% \[[@B35]\]. The edge value was the docking score of corresponding compound and protein. Finally, the DTN consisted of 32 target proteins, 18999 compounds (the UNPD ID, chemical name, formula, molecular weight, and CAS registry number of each compound were listed in Table S1, see Table S1 in Supplementary Material available online at <http://dx.doi.org/10.1155/2013/203614>), and 35076 edges (Supplementary Table S2). The glucocorticoid receptor (P04150) did not have any compounds. The compounds were derived from 1669 medicinal plants distinguished by Latin names. The DTN of potentially active compounds and proteins related with T2DM was used as a bridge to build the relationship between compound or medicinal plant and T2DM.

2.3. Chemical Space Analysis {#sec2.3}
----------------------------

The analysis of the distribution of compounds in the chemical space was conducted by principal component analysis (PCA) module in Discovery Studio. The PCA model was built with 8 descriptors: *A*  log⁡  *P*, molecular weight, number of hydrogen-bond donors, number of hydrogen-bond acceptors, number of rotatable bonds, number of rings, number of aromatic rings, and molecular fractional polar surface area. The variances of PC1, PC2, and PC3 for compounds in [Figure 2](#fig2){ref-type="fig"} were 0.488, 0.186, and 0.145, respectively. The PCA of 25 FDA-approved small-molecule drugs retrieved from DrugBank was performed in the same process as above.

2.4. Prediction Model {#sec2.4}
---------------------

Natural products are multitarget agents. The average number of target proteins was 1.84 in the DTN. Therefore, we proposed that the prediction efficacy (PE) of a compound for T2DM was the sum of its all edge values (docking scores) in the DTN: $$\begin{matrix}
{\text{P}\text{E}_{\text{compound}} = {\sum\limits_{j \in P}^{}{\text{scor}\text{e}_{j}}},} \\
\end{matrix}$$ where *P* was the set of proteins related to T2DM and score~*j*~ was the docking score between this compound and *j*th protein. The PE~compound~ for each compound was listed in Table S3.

Similarly, the prediction efficacy of a medicinal plant was defined as the sum of PE of compounds contained in this plant: $$\begin{matrix}
{\text{P}\text{E}_{\text{plant}} = {\sum\limits_{i}^{N}{\text{P}\text{E}_{\text{compound}_{i}}}},} \\
\end{matrix}$$ where *N* denoted the number of compounds contained in the medicinal plant. The PE~plant~ for each medicinal plant was listed in Table S4.

3. Results and Discussion {#sec3}
=========================

3.1. Drug-Likeness of Medicinal Natural Products for T2DM {#sec3.1}
---------------------------------------------------------

The natural products contained in medicinal plants for T2DM had good drug-like properties. Lipinski CA and colleagues proposed the "rule of five" (molecular weight (MW) less than 500 Da, the number of hydrogen bond acceptors (HBA) less than 10, the number of hydrogen bond donors (HBD) less than 5, and octanol-water partition coefficient (*A*  log⁡  *P*) less than five) \[[@B40], [@B41]\] to estimate solubility and permeability of compounds in drug discovery. That is, a compound was unlikely to be a drug if it disobeyed the rules. The mean and median of MW, HBA, HBD, and *A*  log⁡  *P* of these compounds were 540.43, 494.62; 6.3, 5; 2.5, 2; and 4.94, 5.07; respectively. It indicated that most compounds would be drug-like. The wide distribution of natural products in chemical space ([Figure 2](#fig2){ref-type="fig"}) showed that there would be vast property (structural and functional) diversity. Moreover, the large overlap between natural products and 25 FDA-approved small-molecule drugs for T2DM demonstrated that natural products contained in these medicinal plants had a hopeful prospect for drug discovery for T2DM.

3.2. Prediction Efficacy of Natural Product and Medicinal Plant {#sec3.2}
---------------------------------------------------------------

Herb medicines could simultaneously target multiple physiological processes through interactions between multiple compounds and cellular target proteins. For example, there were 105 distinct compounds contained in *Hypericum perforatum*, and 21 compounds existed in DTN. The herbal medicines could influence the biological system through interactions between multi-component and multi-target and thus reverse the biological networks from disease state to health state. Since a group of compounds contained in the herbal medicine could play a therapeutic role, the dosage could be reduced to reduce toxicity and side effects. For example, UNPD43323 (ormojine), UNPD194973 (ormosinin), and UNPD194973 (strychnohexamine) were the top three potential compounds (Supplementary Table S3). ormojine, ormosinin, and strychnohexamine had 27, 24, and 23 targets, respectively. The polypharmacology of natural products was very common.

The predicted efficacy of the top twenty medicinal plants for T2DM was listed in [Table 2](#tab2){ref-type="table"}. There were five plants (*Hypericum perforatum, Ganoderma lucidum, Holarrhena antidysenterica, Celastrus orbiculatus,*and*Murraya euchrestifolia*) where prediction efficacy was higher than 1000. We searched the literatures which reported the anti-T2DM bioactivities of the top twenty medicinal plants ([Table 2](#tab2){ref-type="table"}) and found that 15 medicinal plants had information of definite effectiveness against T2DM. For example, Arokiyaraj and colleagues evaluated the antihyperglycemic activity of *Hypericum perforatum* in diabetic rats, and it produced significant reduction in plasma glucose level \[[@B42]\].

3.3. Clinical Herbal Formula {#sec3.3}
----------------------------

Tangminling which was a widely used herbal formula in China to treat T2DM comprised eleven medicinal herbs (*Trichosanthes kirilowii*, *Citrus sinensis*, *Bupleurum chinense*, *Rheum officinale*, *Astragalus membranaceus*, *Pinellia ternata*, *Scutellaria discolor*, *Crataegus pinnatifida var*. *major*, *Paeonia albiflora*, *Prunus mume*, and *Picrorhiza kurroa*) \[[@B3]\]. The prediction efficacy of each medicinal plant was 493.04, 199.26, 36.06, 29.08, 15.12, 14.80, 7.83, 7.09, 7.07, 7.06, and 7.04, respectively. It indicated that all plants could play a role in the treatment of T2DM. However, the prediction efficacy of eleven herbs differed considerably from each other. It meant that *Trichosanthes kirilowii* and *Citrus sinensis* played major roles (sovereign herbs). Meanwhile, The others worked as assistants which may strengthen the efficacy of sovereign herbs or reduce the toxicity.

4. Conclusions {#sec4}
==============

Medicinal plants are potentially important for novel therapeutic drugs. It is currently estimated that approximately 420,000 plant species exist in nature \[[@B61]\]. However, only 10,000 of all plants have documented medicinal use \[[@B62]\]. Therefore, there are potentially many more important pharmaceutical applications of plants to be exploited. Traditional method (from selecting plants to separating compounds following bioassay) is time-consuming. In this work, we developed a molecular docking score-weighted prediction model based on drug-target network to evaluate the efficacy of natural products and medicinal plants for T2DM. Natural products contained in the medicinal plants would target several cellular target proteins. The prediction efficacy of this model took into account all potential interactions between multicomponents and targets. Therefore, the prediction efficacy was an overall evaluation at systems level. Fifteen out of the top twenty medicinal plants had reported bioactivity against T2DM in literatures. This approach may promote the research on the use of medicinal plants to treat T2DM and drug discovery from natural products.

Supplementary Material {#supplementary-material-sec}
======================

###### 

The supplementary materials comprise four tables of large datasets. Table S1 listed the identification information of 18999 natural products. Table S2 listed the natural products-target proteins interaction network (DTN). Table S3 and Table S4 listed the prediction efficacy of natural products and medicinal plants for T2DM, respectively.

###### 

Click here for additional data file.
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![The work flow of this approach.](ECAM2013-203614.001){#fig1}

![The distribution in chemical space according to PCA of natural products contained in medicinal plants and 25 FDA-approved drugs for T2DM. The black dots and green triangles represent natural products and FDA-approved drugs, respectively.](ECAM2013-203614.002){#fig2}

###### 

List of 33 proteins related with T2DM for molecular docking.

  Index   UniProt entry   PDB entry   Protein name
  ------- --------------- ----------- --------------------------------------------------------------------------------
  1       O43451          3CTT        Maltase-glucoamylase, intestinal
  2       P01308          1TYM        Insulin
  3       P01375          2AZ5        Tumor necrosis factor alpha
  4       P04150          3H52        Glucocorticoid receptor
  5       P04746          1XDO        Pancreatic alpha-amylase
  6       P05121          3UT3        Plasminogen activator inhibitor 1
  7       P06213          3EKN        Insulin receptor
  8       P07339          1LYW        Cathepsin D
  9       P08069          3I81        Insulin-like growth factor 1 receptor
  10      P11474          3K6P        Steroid hormone receptor ERR1
  11      P12821          3L3N        Angiotensin-converting enzyme
  12      P13569          3GD7        Cystic fibrosis transmembrane conductance regulator
  13      P14410          3LPP        Sucrase-isomaltase, intestinal
  14      P14618          3BJF        Pyruvate kinase isozymes M1/M2
  15      P14735          3E4A        Insulin-degrading enzyme
  16      P19367          1DGK        Hexokinase-1
  17      P27361          2ZOQ        Mitogen-activated protein kinase 3
  18      P27487          3G0D        Dipeptidyl peptidase 4
  19      P27986          4A55        Phosphatidylinositol 3-kinase regulatory subunit alpha
  20      P28482          3I5Z        Mitogen-activated protein kinase 1
  21      P30613          2VGF        Pyruvate kinase isozymes R/L
  22      P35557          3IMX        Glucokinase
  23      P35568          2Z8C        Insulin receptor substrate 1
  24      P37231          3H0A        Peroxisome proliferator-activated receptor gamma
  25      P42336          3HHM        Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
  26      P42345          1FAP        Serine/threonine-protein kinase mTOR
  27      P43220          3C59        Glucagon-like peptide 1 receptor
  28      P45983          3PZE        Mitogen-activated protein kinase 8
  29      P45984          3NPC        Mitogen-activated protein kinase 9
  30      P48736          3SD5        Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
  31      P53779          3TTI        Mitogen-activated protein kinase 10
  32      P62508          2P7A        Estrogen-related receptor gamma
  33      Q9BYF1          1R4L        Angiotensin-converting enzyme 2

###### 

Top twenty potential medicinal plants.

  Rank   Latin name                     PE~plant~   Reported bioactivity
  ------ ------------------------------ ----------- ----------------------
  1      *Hypericum perforatum*         1777.81     \[[@B42], [@B43]\]
  2      *Ganoderma lucidum*            1560.05     \[[@B44]\]
  3      *Holarrhena antidysenterica*   1147.22     \[[@B45], [@B46]\]
  4      *Celastrus orbiculatus*        1089.44     N/A
  5      *Murraya euchrestifolia*       1066.97     N/A
  6      *Melia azedarach*              980.47      \[[@B47]\]
  7      *Datura metel*                 894.36      \[[@B48], [@B49]\]
  8      *Ficus microcarpa*             837.65      \[[@B50]\]
  9      *Tripterygium wilfordii*       785.30      \[[@B51]\]
  10     *Pachysandra terminalis*       740.38      N/A
  11     *Calendula officinalis*        729.77      \[[@B52]\]
  12     *Vitis vinifera*               719.77      \[[@B53]\]
  13     *Melia toosendan*              711.49      N/A
  14     *Mangifera indica*             677.08      \[[@B54]\]
  15     *Piper nigrum*                 667.41      \[[@B55]\]
  16     *Solanum dulcamara*            667.12      \[[@B56]\]
  17     *Garcinia hanburyi*            641.41      N/A
  18     *Momordica charantia*          632.37      \[[@B57], [@B58]\]
  19     *Lantana camara*               625.64      \[[@B59]\]
  20     *Ceriops tagal*                623.13      \[[@B60]\]
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